Atlas of Genetics and Cytogenetics in Oncology and Haematology


Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA

inv(3)(q21q26):t(3;3)(q21;q26):t(3;3)(q26;q21) GATA2/MECOM

Written2018-01Jean-Loup Huret, Philippe Dessen

(Note : for Links provided by Atlas : click)

Identity

ICD-Topo C420,C421,C424 BLOOD, BONE MARROW, & HEMATOPOIETIC SYS
Atlas_Id 2744

Clinics and Pathology

Disease Acute myeloid leukemia, NOS:Chronic myeloid leukemia, t(9;22):Myelodysplastic syndrome, NOS

Genes involved and Proteins

Gene NameGATA2
Location 3q21.3
Gene NameMECOM
Location 3q26.2

To be noted

Non-annotated chromosomal abnormality. Preliminary data : if you are an author who wish to write a full paper/card on the chromosome abnormality, go to  How to contribute

Bibliography

Multivariate analysis of prognostic factors in patients with refractory and relapsed acute myeloid leukemia undergoing sequential high-dose cytosine arabinoside and mitoxantrone (S-HAM) salvage therapy: relevance of cytogenetic abnormalities
Kern W, Schoch C, Haferlach T, Braess J, Unterhalt M, Wörmann B, Büchner T, Hiddemann W
Leukemia 2000 Feb;14(2):226-31
PMID 10673737
 
Survival time in a population-based consecutive series of adult acute myeloid leukemia--the prognostic impact of karyotype during the time period 1976-1993
Mauritzson N, Johansson B, Albin M, Rylander L, Billström R, Ahlgren T, Mikoczy Z, Strömberg U, Mitelman F, Hagmar L, Nilsson PG
Leukemia 2000 Jun;14(6):1039-43
PMID 10865970
 
High-dose cytosine arabinoside and daunorubicin induction therapy for adult patients with de novo non M3 acute myelogenous leukemia: impact of cytogenetics on achieving a complete remission
Stein AS, O'Donnell MR, Slovak ML, Nademanee A, Dagis A, Schmidt GM, Parker PM, Snyder DS, Smith EP, Somlo G, Margolin KA, Arber D, Niland J, Forman SJ
Leukemia 2000 Jul;14(7):1191-6
 
Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study
Slovak ML, Kopecky KJ, Cassileth PA, Harrington DH, Theil KS, Mohamed A, Paietta E, Willman CL, Head DR, Rowe JM, Forman SJ, Appelbaum FR
Blood 2000 Dec 15;96(13):4075-83
PMID 11110676
 
First line therapy with fludarabine combinations in 42 patients with either post myelodysplastic syndrome or therapy related acute myeloid leukaemia
Clavio M, Gatto S, Beltrami G, Cerri R, Carrara P, Pierri I, Canepa L, Miglino M, Balleari E, Masoudi B, Damasio E, Ghio R, Sessarego M, Gobbi M
Leuk Lymphoma 2001 Jan;40(3-4):305-13
PMID 11426552
 
Prognostic significance of risk group stratification in elderly patients with acute myeloid leukaemia
Wahlin A, Markevärn B, Golovleva I, Nilsson M
Br J Haematol 2001 Oct;115(1):25-33
PMID 11722406
 
Structural rearrangements of chromosome 3 in 57 patients with acute myeloid leukemia: clinical, hematological and cytogenetic features
Charrin C, Belhabri A, Treille-Ritouet D, Theuil G, Magaud JP, Fiere D, Thomas X
Hematol J 2002;3(1):21-31
PMID 11960392
 
Karyotype instability between diagnosis and relapse in 117 patients with acute myeloid leukemia: implications for resistance against therapy
Kern W, Haferlach T, Schnittger S, Ludwig WD, Hiddemann W, Schoch C
Leukemia 2002 Oct;16(10):2084-91
PMID 12357361
 
Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial
Kern W, Haferlach T, Schoch C, Loffler H, Gassmann W, Heinecke A, Sauerland MC, Berdel W, Buchner T, Hiddemann W
Blood 2003 Jan 1;101(1):64-70
PMID 12393605
 
Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)
Byrd JC, Mrózek K, Dodge RK, Carroll AJ, Edwards CG, Arthur DC, Pettenati MJ, Patil SR, Rao KW, Watson MS, Koduru PR, Moore JO, Stone RM, Mayer RJ, Feldman EJ, Davey FR, Schiffer CA, Larson RA, Bloomfield CD; Cancer and Leukemia Group B (CALGB 8461)
Blood 2002 Dec 15;100(13):4325-36
PMID 12393746
 
Morphologic dysplasia in de novo acute myeloid leukemia (AML) is related to unfavorable cytogenetics but has no independent prognostic relevance under the conditions of intensive induction therapy: results of a multiparameter analysis from the German AML Cooperative Group studies
Haferlach T, Schoch C, Löffler H, Gassmann W, Kern W, Schnittger S, Fonatsch C, Ludwig WD, Wuchter C, Schlegelberger B, Staib P, Reichle A, Kubica U, Eimermacher H, Balleisen L, Grüneisen A, Haase D, Aul C, Karow J, Lengfelder E, Wörmann B, Heinecke A, Sauerland MC, Büchner T, Hiddemann W
J Clin Oncol 2003 Jan 15;21(2):256-65
PMID 12525517
 
Low expression of the myeloid differentiation antigen CD65s, a feature of poorly differentiated AML in older adults: study of 711 patients enrolled in ECOG trials
Paietta E, Neuberg D, Bennett JM, Dewald G, Rowe JM, Cassileth PA, Cripe L, Tallman MS, Wiernik PH; Eastern Cooperative Oncology Group
Leukemia 2003 Aug;17(8):1544-50
PMID 12886241
 
The influence of age on prognosis of de novo acute myeloid leukemia differs according to cytogenetic subgroups
Schoch C, Kern W, Schnittger S, Büchner T, Hiddemann W, Haferlach T
Haematologica 2004 Sep;89(9):1082-90
PMID 15377469
 
Further correlations of morphology according to FAB and WHO classification to cytogenetics in de novo acute myeloid leukemia: a study on 2,235 patients
Bacher U, Kern W, Schnittger S, Hiddemann W, Schoch C, Haferlach T
Ann Hematol 2005 Nov;84(12):785-91
PMID 16132906
 
Monosomy 7 and deletion 7q in children and adolescents with acute myeloid leukemia: an international retrospective study
Hasle H, Alonzo TA, Auvrignon A, Behar C, Chang M, Creutzig U, Fischer A, Forestier E, Fynn A, Haas OA, Harbott J, Harrison CJ, Heerema NA, van den Heuvel-Eibrink MM, Kaspers GJ, Locatelli F, Noellke P, Polychronopoulou S, Ravindranath Y, Razzouk B, Reinhardt D, Savva NN, Stark B, Suciu S, Tsukimoto I, Webb DK, Wojcik D, Woods WG, Zimmermann M, Niemeyer CM, Raimondi SC
Blood 2007 Jun 1;109(11):4641-7
PMID 17299091
 
Impact of cytogenetics on outcome of matched unrelated donor hematopoietic stem cell transplantation for acute myeloid leukemia in first or second complete remission
Tallman MS, Dewald GW, Gandham S, Logan BR, Keating A, Lazarus HM, Litzow MR, Mehta J, Pedersen T, Pérez WS, Rowe JM, Wetzler M, Weisdorf DJ
Blood 2007 Jul 1;110(1):409-17
PMID 17374741
 
Advanced age and high initial WBC influence the outcome of inv(3) (q21q26)/t(3;3) (q21;q26) positive AML
Weisser M, Haferlach C, Haferlach T, Schnittger S
Leuk Lymphoma 2007 Nov;48(11):2145-51
PMID 17926191
 
Long-term follow-up of allogeneic hematopoietic stem cell transplantation for de novo acute myelogenous leukemia with a conditioning regimen of total body irradiation and granulocyte colony-stimulating factor-combined high-dose cytarabine
Mori T, Aisa Y, Watanabe R, Yamazaki R, Kato J, Shimizu T, Shigematsu N, Kubo A, Yajima T, Hibi T, Ikeda Y, Okamoto S
Biol Blood Marrow Transplant 2008 Jun;14(6):651-7
PMID 18489990
 
Prognostic impact of genetic characterization in the GIMEMA LAM99P multicenter study for newly diagnosed acute myeloid leukemia
Lo-Coco F, Cuneo A, Pane F, Cilloni D, Diverio D, Mancini M, Testoni N, Bardi A, Izzo B, Bolli N, La Starza R, Fazi P, Iacobelli S, Piciocchi A, Vignetti M, Amadori S, Mandelli F, Pelicci PG, Mecucci C, Falini B, Saglio G; Acute Leukemia Working Party of the GIMEMA group
Haematologica 2008 Jul;93(7):1017-24
PMID 18508799
 
Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia
Schlenk RF, Döhner K, Kneba M, Götze K, Hartmann F, Del Valle F, Kirchen H, Koller E, Fischer JT, Bullinger L, Habdank M, Späth D, Groner S, Krebs B, Kayser S, Corbacioglu A, Anhalt A, Benner A, Fröhling S, Döhner H; German-Austrian AML Study Group (AMLSG)
Results from the AMLSG Trial AML HD98B Haematologica
PMID 19059939
 
Results of risk-adapted therapy in acute myeloid leukaemia
Wahlin A, Billström R, Björ O, Ahlgren T, Hedenus M, Höglund M, Lindmark A, Markevärn B, Nilsson B, Sallerfors B, Brune M
A long-term population-based follow-up study Eur J Haematol
PMID 19385987
 
Immunophenotypic features of acute myeloid leukemia with inv(3)(q21q26
Medeiros BC, Kohrt HE, Arber DA, Bangs CD, Cherry AM, Majeti R, Kogel KE, Azar CA, Patel S, Alizadeh AA
2)/t(3;3)(q21;q26 2)
PMID 19781775
 
Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials
Grimwade D, Hills RK, Moorman AV, Walker H, Chatters S, Goldstone AH, Wheatley K, Harrison CJ, Burnett AK; National Cancer Research Institute Adult Leukaemia Working Group
Blood 2010 Jul 22;116(3):354-65
PMID 20385793
 
Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26
Lugthart S, Gröschel S, Beverloo HB, Kayser S, Valk PJ, van Zelderen-Bhola SL, Jan Ossenkoppele G, Vellenga E, van den Berg-de Ruiter E, Schanz U, Verhoef G, Vandenberghe P, Ferrant A, Köhne CH, Pfreundschuh M, Horst HA, Koller E, von Lilienfeld-Toal M, Bentz M, Ganser A, Schlegelberger B, Jotterand M, Krauter J, Pabst T, Theobald M, Schlenk RF, Delwel R, Döhner K, Löwenberg B, Döhner H
2)/t(3;3)(q21;q26 2) and various other 3q abnormalities in acute myeloid leukemia
PMID 20660833
 
De novo acute myeloid leukemia with inv(3)(q21q26
Sun J, Konoplev SN, Wang X, Cui W, Chen SS, Medeiros LJ, Lin P
2) or t(3;3)(q21;q26 2): a clinicopathologic and cytogenetic study of an entity recently added to the WHO classification
PMID 21113141
 
The inv(3)(q21q26)/t(3;3)(q21;q26) is frequently accompanied by alterations of the RUNX1, KRAS and NRAS and NF1 genes and mediates adverse prognosis both in MDS and in AML: a study in 39 cases of MDS or AML
Haferlach C, Bacher U, Haferlach T, Dicker F, Alpermann T, Kern W, Schnittger S
Leukemia 2011 May;25(5):874-7
PMID 21283084
 
Myelodysplastic syndrome/acute myeloid leukemia with t(3;21)(q26
Li S, Yin CC, Medeiros LJ, Bueso-Ramos C, Lu G, Lin P
2;q22) is commonly a therapy-related disease associated with poor outcome Am J Clin Pathol
PMID 22706870
 
Complex or monosomal karyotype and not blast percentage is associated with poor survival in acute myeloid leukemia and myelodysplastic syndrome patients with inv(3)(q21q26
Rogers HJ, Vardiman JW, Anastasi J, Raca G, Savage NM, Cherry AM, Arber D, Moore E, Morrissette JJ, Bagg A, Liu YC, Mathew S, Orazi A, Lin P, Wang SA, Bueso-Ramos CE, Foucar K, Hasserjian RP, Tiu RV, Karafa M, Hsi ED
2)/t(3;3)(q21;q26 2): a Bone Marrow Pathology Group study
PMID 24463215
 
Incidence and prognostic significance of karyotypic subgroups in older patients with acute myeloid leukemia: the Swedish population-based experience
Lazarevic V, Hörstedt AS, Johansson B, Antunovic P, Billström R, Derolf A, Hulegårdh E, Lehmann S, Möllgård L, Nilsson C, Peterson S, Stockelberg D, Uggla B, Wennström L, Wahlin A, Höglund M, Juliusson G
Blood Cancer J 2014 Feb 28;4:e188
PMID 24583534
 
A single oncogenic enhancer rearrangement causes concomitant EVI1 and GATA2 deregulation in leukemia
Gröschel S, Sanders MA, Hoogenboezem R, de Wit E, Bouwman BAM, Erpelinck C, van der Velden VHJ, Havermans M, Avellino R, van Lom K, Rombouts EJ, van Duin M, Döhner K, Beverloo HB, Bradner JE, Döhner H, Löwenberg B, Valk PJM, Bindels EMJ, de Laat W, Delwel R
Cell 2014 Apr 10;157(2):369-381
PMID 24703711
 
The landscape and therapeutic relevance of cancer-associated transcript fusions
Yoshihara K, Wang Q, Torres-Garcia W, Zheng S, Vegesna R, Kim H, Verhaak RG
Oncogene 2015 Sep 10;34(37):4845-54
PMID 25500544
 
Acute leukemia with abnormal thrombopoiesis and inversions of chromosome 3
Jenkins RB, Tefferi A, Solberg LA Jr, Dewald GW
Cancer Genet Cytogenet 1989 Jun;39(2):167-79
PMID 2752370
 
Clinical correlations of the 3q21;q26 cytogenetic anomaly
Pintado T, Ferro MT, San Román C, Mayayo M, Laraña JG
A leukemic or myelodysplastic syndrome with preserved or increased platelet production and lack of response to cytotoxic drug therapy Cancer
PMID 3965107
 
Rearrangements of chromosome 3 involving bands 3q21 and 3q26 are associated with normal or elevated platelet counts in acute nonlymphocytic leukemia
Bitter MA, Neilly ME, Le Beau MM, Pearson MG, Rowley JD
Blood 1985 Dec;66(6):1362-70
PMID 4063525
 
The predictive value of initial cytogenetic studies in 148 adults with acute nonlymphocytic leukemia: a 12-year study (1970-1982)
Larson RA, Le Beau MM, Vardiman JW, Testa JR, Golomb HM, Rowley JD
Cancer Genet Cytogenet 1983 Nov;10(3):219-36
PMID 6627222
 
Chromosome 3 abnormalities in acute nonlymphocytic leukemia (ANLL) with abnormal thrombopoiesis: report of three patients with a "new" inversion anomaly and a further case of homologous translocation
Bernstein R, Pinto MR, Behr A, Mendelow B
Blood 1982 Sep;60(3):613-7
PMID 7104489
 
Correlation of clinical findings with quinacrine-banded chromosomes in 90 adults with acute nonlymphocytic leukemia: an eight-year study (1970-1977)
Golomb HM, Vardiman JW, Rowley JD, Testa JR, Mintz U
N Engl J Med 1978 Sep 21;299(12):613-9
PMID 79982
 
Correlation of cytogenetic findings with clinical features in 18 patients with inv(3)(q21q26) or t(3;3)(q21;q26)
Fonatsch C, Gudat H, Lengfelder E, Wandt H, Silling-Engelhardt G, Ludwig WD, Thiel E, Freund M, Bodenstein H, Schwieder G, et al
Leukemia 1994 Aug;8(8):1318-26
PMID 8057667
 
Clinical, haematological and cytogenetic features in 24 patients with structural rearrangements of the Q arm of chromosome 3
Grigg AP, Gascoyne RD, Phillips GL, Horsman DE
Br J Haematol 1993 Jan;83(1):158-65
PMID 8435325
 
Abnormalities of 3q21 and 3q26 in myeloid malignancy: a United Kingdom Cancer Cytogenetic Group study
Secker-Walker LM, Mehta A, Bain B
Br J Haematol 1995 Oct;91(2):490-501
PMID 8547101
 
Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy
Leith CP, Kopecky KJ, Godwin J, McConnell T, Slovak ML, Chen IM, Head DR, Appelbaum FR, Willman CL
A Southwest Oncology Group study Blood
PMID 9129038
 
Activation of a novel gene in 3q21 and identification of intergenic fusion transcripts with ecotropic viral insertion site I in leukemia
Pekarsky Y, Rynditch A, Wieser R, Fonatsch C, Gardiner K
Cancer Res 1997 Sep 15;57(18):3914-9
PMID 9307271
 
Multivariate analysis of prognostic factors in patients with refractory and relapsed acute myeloid leukemia undergoing sequential high-dose cytosine arabinoside and mitoxantrone (S-HAM) salvage therapy: relevance of cytogenetic abnormalities
Kern W, Schoch C, Haferlach T, Braess J, Unterhalt M, Wörmann B, Büchner T, Hiddemann W
Leukemia 2000 Feb;14(2):226-31
PMID 10673737
 
Survival time in a population-based consecutive series of adult acute myeloid leukemia--the prognostic impact of karyotype during the time period 1976-1993
Mauritzson N, Johansson B, Albin M, Rylander L, Billström R, Ahlgren T, Mikoczy Z, Strömberg U, Mitelman F, Hagmar L, Nilsson PG
Leukemia 2000 Jun;14(6):1039-43
PMID 10865970
 
High-dose cytosine arabinoside and daunorubicin induction therapy for adult patients with de novo non M3 acute myelogenous leukemia: impact of cytogenetics on achieving a complete remission
Stein AS, O'Donnell MR, Slovak ML, Nademanee A, Dagis A, Schmidt GM, Parker PM, Snyder DS, Smith EP, Somlo G, Margolin KA, Arber D, Niland J, Forman SJ
Leukemia 2000 Jul;14(7):1191-6
 
Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study
Slovak ML, Kopecky KJ, Cassileth PA, Harrington DH, Theil KS, Mohamed A, Paietta E, Willman CL, Head DR, Rowe JM, Forman SJ, Appelbaum FR
Blood 2000 Dec 15;96(13):4075-83
PMID 11110676
 
First line therapy with fludarabine combinations in 42 patients with either post myelodysplastic syndrome or therapy related acute myeloid leukaemia
Clavio M, Gatto S, Beltrami G, Cerri R, Carrara P, Pierri I, Canepa L, Miglino M, Balleari E, Masoudi B, Damasio E, Ghio R, Sessarego M, Gobbi M
Leuk Lymphoma 2001 Jan;40(3-4):305-13
PMID 11426552
 
Prognostic significance of risk group stratification in elderly patients with acute myeloid leukaemia
Wahlin A, Markevärn B, Golovleva I, Nilsson M
Br J Haematol 2001 Oct;115(1):25-33
PMID 11722406
 
Structural rearrangements of chromosome 3 in 57 patients with acute myeloid leukemia: clinical, hematological and cytogenetic features
Charrin C, Belhabri A, Treille-Ritouet D, Theuil G, Magaud JP, Fiere D, Thomas X
Hematol J 2002;3(1):21-31
PMID 11960392
 
Karyotype instability between diagnosis and relapse in 117 patients with acute myeloid leukemia: implications for resistance against therapy
Kern W, Haferlach T, Schnittger S, Ludwig WD, Hiddemann W, Schoch C
Leukemia 2002 Oct;16(10):2084-91
PMID 12357361
 
Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial
Kern W, Haferlach T, Schoch C, Loffler H, Gassmann W, Heinecke A, Sauerland MC, Berdel W, Buchner T, Hiddemann W
Blood 2003 Jan 1;101(1):64-70
PMID 12393605
 
Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)
Byrd JC, Mrózek K, Dodge RK, Carroll AJ, Edwards CG, Arthur DC, Pettenati MJ, Patil SR, Rao KW, Watson MS, Koduru PR, Moore JO, Stone RM, Mayer RJ, Feldman EJ, Davey FR, Schiffer CA, Larson RA, Bloomfield CD; Cancer and Leukemia Group B (CALGB 8461)
Blood 2002 Dec 15;100(13):4325-36
PMID 12393746
 
Morphologic dysplasia in de novo acute myeloid leukemia (AML) is related to unfavorable cytogenetics but has no independent prognostic relevance under the conditions of intensive induction therapy: results of a multiparameter analysis from the German AML Cooperative Group studies
Haferlach T, Schoch C, Löffler H, Gassmann W, Kern W, Schnittger S, Fonatsch C, Ludwig WD, Wuchter C, Schlegelberger B, Staib P, Reichle A, Kubica U, Eimermacher H, Balleisen L, Grüneisen A, Haase D, Aul C, Karow J, Lengfelder E, Wörmann B, Heinecke A, Sauerland MC, Büchner T, Hiddemann W
J Clin Oncol 2003 Jan 15;21(2):256-65
PMID 12525517
 
Low expression of the myeloid differentiation antigen CD65s, a feature of poorly differentiated AML in older adults: study of 711 patients enrolled in ECOG trials
Paietta E, Neuberg D, Bennett JM, Dewald G, Rowe JM, Cassileth PA, Cripe L, Tallman MS, Wiernik PH; Eastern Cooperative Oncology Group
Leukemia 2003 Aug;17(8):1544-50
PMID 12886241
 
The influence of age on prognosis of de novo acute myeloid leukemia differs according to cytogenetic subgroups
Schoch C, Kern W, Schnittger S, Büchner T, Hiddemann W, Haferlach T
Haematologica 2004 Sep;89(9):1082-90
PMID 15377469
 
Further correlations of morphology according to FAB and WHO classification to cytogenetics in de novo acute myeloid leukemia: a study on 2,235 patients
Bacher U, Kern W, Schnittger S, Hiddemann W, Schoch C, Haferlach T
Ann Hematol 2005 Nov;84(12):785-91
PMID 16132906
 
Monosomy 7 and deletion 7q in children and adolescents with acute myeloid leukemia: an international retrospective study
Hasle H, Alonzo TA, Auvrignon A, Behar C, Chang M, Creutzig U, Fischer A, Forestier E, Fynn A, Haas OA, Harbott J, Harrison CJ, Heerema NA, van den Heuvel-Eibrink MM, Kaspers GJ, Locatelli F, Noellke P, Polychronopoulou S, Ravindranath Y, Razzouk B, Reinhardt D, Savva NN, Stark B, Suciu S, Tsukimoto I, Webb DK, Wojcik D, Woods WG, Zimmermann M, Niemeyer CM, Raimondi SC
Blood 2007 Jun 1;109(11):4641-7
PMID 17299091
 
Impact of cytogenetics on outcome of matched unrelated donor hematopoietic stem cell transplantation for acute myeloid leukemia in first or second complete remission
Tallman MS, Dewald GW, Gandham S, Logan BR, Keating A, Lazarus HM, Litzow MR, Mehta J, Pedersen T, Pérez WS, Rowe JM, Wetzler M, Weisdorf DJ
Blood 2007 Jul 1;110(1):409-17
PMID 17374741
 
Advanced age and high initial WBC influence the outcome of inv(3) (q21q26)/t(3;3) (q21;q26) positive AML
Weisser M, Haferlach C, Haferlach T, Schnittger S
Leuk Lymphoma 2007 Nov;48(11):2145-51
PMID 17926191
 
Long-term follow-up of allogeneic hematopoietic stem cell transplantation for de novo acute myelogenous leukemia with a conditioning regimen of total body irradiation and granulocyte colony-stimulating factor-combined high-dose cytarabine
Mori T, Aisa Y, Watanabe R, Yamazaki R, Kato J, Shimizu T, Shigematsu N, Kubo A, Yajima T, Hibi T, Ikeda Y, Okamoto S
Biol Blood Marrow Transplant 2008 Jun;14(6):651-7
PMID 18489990
 
Prognostic impact of genetic characterization in the GIMEMA LAM99P multicenter study for newly diagnosed acute myeloid leukemia
Lo-Coco F, Cuneo A, Pane F, Cilloni D, Diverio D, Mancini M, Testoni N, Bardi A, Izzo B, Bolli N, La Starza R, Fazi P, Iacobelli S, Piciocchi A, Vignetti M, Amadori S, Mandelli F, Pelicci PG, Mecucci C, Falini B, Saglio G; Acute Leukemia Working Party of the GIMEMA group
Haematologica 2008 Jul;93(7):1017-24
PMID 18508799
 
Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia
Schlenk RF, Döhner K, Kneba M, Götze K, Hartmann F, Del Valle F, Kirchen H, Koller E, Fischer JT, Bullinger L, Habdank M, Späth D, Groner S, Krebs B, Kayser S, Corbacioglu A, Anhalt A, Benner A, Fröhling S, Döhner H; German-Austrian AML Study Group (AMLSG)
Results from the AMLSG Trial AML HD98B Haematologica
PMID 19059939
 
Results of risk-adapted therapy in acute myeloid leukaemia
Wahlin A, Billström R, Björ O, Ahlgren T, Hedenus M, Höglund M, Lindmark A, Markevärn B, Nilsson B, Sallerfors B, Brune M
A long-term population-based follow-up study Eur J Haematol
PMID 19385987
 
Immunophenotypic features of acute myeloid leukemia with inv(3)(q21q26
Medeiros BC, Kohrt HE, Arber DA, Bangs CD, Cherry AM, Majeti R, Kogel KE, Azar CA, Patel S, Alizadeh AA
2)/t(3;3)(q21;q26 2)
PMID 19781775
 
Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials
Grimwade D, Hills RK, Moorman AV, Walker H, Chatters S, Goldstone AH, Wheatley K, Harrison CJ, Burnett AK; National Cancer Research Institute Adult Leukaemia Working Group
Blood 2010 Jul 22;116(3):354-65
PMID 20385793
 
Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26
Lugthart S, Gröschel S, Beverloo HB, Kayser S, Valk PJ, van Zelderen-Bhola SL, Jan Ossenkoppele G, Vellenga E, van den Berg-de Ruiter E, Schanz U, Verhoef G, Vandenberghe P, Ferrant A, Köhne CH, Pfreundschuh M, Horst HA, Koller E, von Lilienfeld-Toal M, Bentz M, Ganser A, Schlegelberger B, Jotterand M, Krauter J, Pabst T, Theobald M, Schlenk RF, Delwel R, Döhner K, Löwenberg B, Döhner H
2)/t(3;3)(q21;q26 2) and various other 3q abnormalities in acute myeloid leukemia
PMID 20660833
 
De novo acute myeloid leukemia with inv(3)(q21q26
Sun J, Konoplev SN, Wang X, Cui W, Chen SS, Medeiros LJ, Lin P
2) or t(3;3)(q21;q26 2): a clinicopathologic and cytogenetic study of an entity recently added to the WHO classification
PMID 21113141
 
The inv(3)(q21q26)/t(3;3)(q21;q26) is frequently accompanied by alterations of the RUNX1, KRAS and NRAS and NF1 genes and mediates adverse prognosis both in MDS and in AML: a study in 39 cases of MDS or AML
Haferlach C, Bacher U, Haferlach T, Dicker F, Alpermann T, Kern W, Schnittger S
Leukemia 2011 May;25(5):874-7
PMID 21283084
 
Myelodysplastic syndrome/acute myeloid leukemia with t(3;21)(q26
Li S, Yin CC, Medeiros LJ, Bueso-Ramos C, Lu G, Lin P
2;q22) is commonly a therapy-related disease associated with poor outcome Am J Clin Pathol
PMID 22706870
 
Complex or monosomal karyotype and not blast percentage is associated with poor survival in acute myeloid leukemia and myelodysplastic syndrome patients with inv(3)(q21q26
Rogers HJ, Vardiman JW, Anastasi J, Raca G, Savage NM, Cherry AM, Arber D, Moore E, Morrissette JJ, Bagg A, Liu YC, Mathew S, Orazi A, Lin P, Wang SA, Bueso-Ramos CE, Foucar K, Hasserjian RP, Tiu RV, Karafa M, Hsi ED
2)/t(3;3)(q21;q26 2): a Bone Marrow Pathology Group study
PMID 24463215
 
Incidence and prognostic significance of karyotypic subgroups in older patients with acute myeloid leukemia: the Swedish population-based experience
Lazarevic V, Hörstedt AS, Johansson B, Antunovic P, Billström R, Derolf A, Hulegårdh E, Lehmann S, Möllgård L, Nilsson C, Peterson S, Stockelberg D, Uggla B, Wennström L, Wahlin A, Höglund M, Juliusson G
Blood Cancer J 2014 Feb 28;4:e188
PMID 24583534
 
A single oncogenic enhancer rearrangement causes concomitant EVI1 and GATA2 deregulation in leukemia
Gröschel S, Sanders MA, Hoogenboezem R, de Wit E, Bouwman BAM, Erpelinck C, van der Velden VHJ, Havermans M, Avellino R, van Lom K, Rombouts EJ, van Duin M, Döhner K, Beverloo HB, Bradner JE, Döhner H, Löwenberg B, Valk PJM, Bindels EMJ, de Laat W, Delwel R
Cell 2014 Apr 10;157(2):369-381
PMID 24703711
 
Acute leukemia with abnormal thrombopoiesis and inversions of chromosome 3
Jenkins RB, Tefferi A, Solberg LA Jr, Dewald GW
Cancer Genet Cytogenet 1989 Jun;39(2):167-79
PMID 2752370
 
Clinical correlations of the 3q21;q26 cytogenetic anomaly
Pintado T, Ferro MT, San Román C, Mayayo M, Laraña JG
A leukemic or myelodysplastic syndrome with preserved or increased platelet production and lack of response to cytotoxic drug therapy Cancer
PMID 3965107
 
Rearrangements of chromosome 3 involving bands 3q21 and 3q26 are associated with normal or elevated platelet counts in acute nonlymphocytic leukemia
Bitter MA, Neilly ME, Le Beau MM, Pearson MG, Rowley JD
Blood 1985 Dec;66(6):1362-70
PMID 4063525
 
Chromosome 3 abnormalities in acute nonlymphocytic leukemia (ANLL) with abnormal thrombopoiesis: report of three patients with a "new" inversion anomaly and a further case of homologous translocation
Bernstein R, Pinto MR, Behr A, Mendelow B
Blood 1982 Sep;60(3):613-7
PMID 7104489
 
Correlation of cytogenetic findings with clinical features in 18 patients with inv(3)(q21q26) or t(3;3)(q21;q26)
Fonatsch C, Gudat H, Lengfelder E, Wandt H, Silling-Engelhardt G, Ludwig WD, Thiel E, Freund M, Bodenstein H, Schwieder G, et al
Leukemia 1994 Aug;8(8):1318-26
PMID 8057667
 
Clinical, haematological and cytogenetic features in 24 patients with structural rearrangements of the Q arm of chromosome 3
Grigg AP, Gascoyne RD, Phillips GL, Horsman DE
Br J Haematol 1993 Jan;83(1):158-65
PMID 8435325
 
Abnormalities of 3q21 and 3q26 in myeloid malignancy: a United Kingdom Cancer Cytogenetic Group study
Secker-Walker LM, Mehta A, Bain B
Br J Haematol 1995 Oct;91(2):490-501
PMID 8547101
 
Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy
Leith CP, Kopecky KJ, Godwin J, McConnell T, Slovak ML, Chen IM, Head DR, Appelbaum FR, Willman CL
A Southwest Oncology Group study Blood
PMID 9129038
 
A single oncogenic enhancer rearrangement causes concomitant EVI1 and GATA2 deregulation in leukemia
Gröschel S, Sanders MA, Hoogenboezem R, de Wit E, Bouwman BAM, Erpelinck C, van der Velden VHJ, Havermans M, Avellino R, van Lom K, Rombouts EJ, van Duin M, Döhner K, Beverloo HB, Bradner JE, Döhner H, Löwenberg B, Valk PJM, Bindels EMJ, de Laat W, Delwel R
Cell 2014 Apr 10;157(2):369-381
PMID 24703711
 
Multivariate analysis of prognostic factors in patients with refractory and relapsed acute myeloid leukemia undergoing sequential high-dose cytosine arabinoside and mitoxantrone (S-HAM) salvage therapy: relevance of cytogenetic abnormalities
Kern W, Schoch C, Haferlach T, Braess J, Unterhalt M, Wörmann B, Büchner T, Hiddemann W
Leukemia 2000 Feb;14(2):226-31
PMID 10673737
 
Prognostic significance of risk group stratification in elderly patients with acute myeloid leukaemia
Wahlin A, Markevärn B, Golovleva I, Nilsson M
Br J Haematol 2001 Oct;115(1):25-33
PMID 11722406
 
Structural rearrangements of chromosome 3 in 57 patients with acute myeloid leukemia: clinical, hematological and cytogenetic features
Charrin C, Belhabri A, Treille-Ritouet D, Theuil G, Magaud JP, Fiere D, Thomas X
Hematol J 2002;3(1):21-31
PMID 11960392
 
Karyotype instability between diagnosis and relapse in 117 patients with acute myeloid leukemia: implications for resistance against therapy
Kern W, Haferlach T, Schnittger S, Ludwig WD, Hiddemann W, Schoch C
Leukemia 2002 Oct;16(10):2084-91
PMID 12357361
 
Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial
Kern W, Haferlach T, Schoch C, Loffler H, Gassmann W, Heinecke A, Sauerland MC, Berdel W, Buchner T, Hiddemann W
Blood 2003 Jan 1;101(1):64-70
PMID 12393605
 
Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)
Byrd JC, Mrózek K, Dodge RK, Carroll AJ, Edwards CG, Arthur DC, Pettenati MJ, Patil SR, Rao KW, Watson MS, Koduru PR, Moore JO, Stone RM, Mayer RJ, Feldman EJ, Davey FR, Schiffer CA, Larson RA, Bloomfield CD; Cancer and Leukemia Group B (CALGB 8461)
Blood 2002 Dec 15;100(13):4325-36
PMID 12393746
 
Morphologic dysplasia in de novo acute myeloid leukemia (AML) is related to unfavorable cytogenetics but has no independent prognostic relevance under the conditions of intensive induction therapy: results of a multiparameter analysis from the German AML Cooperative Group studies
Haferlach T, Schoch C, Löffler H, Gassmann W, Kern W, Schnittger S, Fonatsch C, Ludwig WD, Wuchter C, Schlegelberger B, Staib P, Reichle A, Kubica U, Eimermacher H, Balleisen L, Grüneisen A, Haase D, Aul C, Karow J, Lengfelder E, Wörmann B, Heinecke A, Sauerland MC, Büchner T, Hiddemann W
J Clin Oncol 2003 Jan 15;21(2):256-65
PMID 12525517
 
Low expression of the myeloid differentiation antigen CD65s, a feature of poorly differentiated AML in older adults: study of 711 patients enrolled in ECOG trials
Paietta E, Neuberg D, Bennett JM, Dewald G, Rowe JM, Cassileth PA, Cripe L, Tallman MS, Wiernik PH; Eastern Cooperative Oncology Group
Leukemia 2003 Aug;17(8):1544-50
PMID 12886241
 
The influence of age on prognosis of de novo acute myeloid leukemia differs according to cytogenetic subgroups
Schoch C, Kern W, Schnittger S, Büchner T, Hiddemann W, Haferlach T
Haematologica 2004 Sep;89(9):1082-90
PMID 15377469
 
Further correlations of morphology according to FAB and WHO classification to cytogenetics in de novo acute myeloid leukemia: a study on 2,235 patients
Bacher U, Kern W, Schnittger S, Hiddemann W, Schoch C, Haferlach T
Ann Hematol 2005 Nov;84(12):785-91
PMID 16132906
 
Monosomy 7 and deletion 7q in children and adolescents with acute myeloid leukemia: an international retrospective study
Hasle H, Alonzo TA, Auvrignon A, Behar C, Chang M, Creutzig U, Fischer A, Forestier E, Fynn A, Haas OA, Harbott J, Harrison CJ, Heerema NA, van den Heuvel-Eibrink MM, Kaspers GJ, Locatelli F, Noellke P, Polychronopoulou S, Ravindranath Y, Razzouk B, Reinhardt D, Savva NN, Stark B, Suciu S, Tsukimoto I, Webb DK, Wojcik D, Woods WG, Zimmermann M, Niemeyer CM, Raimondi SC
Blood 2007 Jun 1;109(11):4641-7
PMID 17299091
 
Impact of cytogenetics on outcome of matched unrelated donor hematopoietic stem cell transplantation for acute myeloid leukemia in first or second complete remission
Tallman MS, Dewald GW, Gandham S, Logan BR, Keating A, Lazarus HM, Litzow MR, Mehta J, Pedersen T, Pérez WS, Rowe JM, Wetzler M, Weisdorf DJ
Blood 2007 Jul 1;110(1):409-17
PMID 17374741
 
Advanced age and high initial WBC influence the outcome of inv(3) (q21q26)/t(3;3) (q21;q26) positive AML
Weisser M, Haferlach C, Haferlach T, Schnittger S
Leuk Lymphoma 2007 Nov;48(11):2145-51
PMID 17926191
 
Prognostic impact of genetic characterization in the GIMEMA LAM99P multicenter study for newly diagnosed acute myeloid leukemia
Lo-Coco F, Cuneo A, Pane F, Cilloni D, Diverio D, Mancini M, Testoni N, Bardi A, Izzo B, Bolli N, La Starza R, Fazi P, Iacobelli S, Piciocchi A, Vignetti M, Amadori S, Mandelli F, Pelicci PG, Mecucci C, Falini B, Saglio G; Acute Leukemia Working Party of the GIMEMA group
Haematologica 2008 Jul;93(7):1017-24
PMID 18508799
 
Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia
Schlenk RF, Döhner K, Kneba M, Götze K, Hartmann F, Del Valle F, Kirchen H, Koller E, Fischer JT, Bullinger L, Habdank M, Späth D, Groner S, Krebs B, Kayser S, Corbacioglu A, Anhalt A, Benner A, Fröhling S, Döhner H; German-Austrian AML Study Group (AMLSG)
Results from the AMLSG Trial AML HD98B Haematologica
PMID 19059939
 
Results of risk-adapted therapy in acute myeloid leukaemia
Wahlin A, Billström R, Björ O, Ahlgren T, Hedenus M, Höglund M, Lindmark A, Markevärn B, Nilsson B, Sallerfors B, Brune M
A long-term population-based follow-up study Eur J Haematol
PMID 19385987
 
Immunophenotypic features of acute myeloid leukemia with inv(3)(q21q26
Medeiros BC, Kohrt HE, Arber DA, Bangs CD, Cherry AM, Majeti R, Kogel KE, Azar CA, Patel S, Alizadeh AA
2)/t(3;3)(q21;q26 2)
PMID 19781775
 
Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials
Grimwade D, Hills RK, Moorman AV, Walker H, Chatters S, Goldstone AH, Wheatley K, Harrison CJ, Burnett AK; National Cancer Research Institute Adult Leukaemia Working Group
Blood 2010 Jul 22;116(3):354-65
PMID 20385793
 
Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26
Lugthart S, Gröschel S, Beverloo HB, Kayser S, Valk PJ, van Zelderen-Bhola SL, Jan Ossenkoppele G, Vellenga E, van den Berg-de Ruiter E, Schanz U, Verhoef G, Vandenberghe P, Ferrant A, Köhne CH, Pfreundschuh M, Horst HA, Koller E, von Lilienfeld-Toal M, Bentz M, Ganser A, Schlegelberger B, Jotterand M, Krauter J, Pabst T, Theobald M, Schlenk RF, Delwel R, Döhner K, Löwenberg B, Döhner H
2)/t(3;3)(q21;q26 2) and various other 3q abnormalities in acute myeloid leukemia
PMID 20660833
 
De novo acute myeloid leukemia with inv(3)(q21q26
Sun J, Konoplev SN, Wang X, Cui W, Chen SS, Medeiros LJ, Lin P
2) or t(3;3)(q21;q26 2): a clinicopathologic and cytogenetic study of an entity recently added to the WHO classification
PMID 21113141
 
The inv(3)(q21q26)/t(3;3)(q21;q26) is frequently accompanied by alterations of the RUNX1, KRAS and NRAS and NF1 genes and mediates adverse prognosis both in MDS and in AML: a study in 39 cases of MDS or AML
Haferlach C, Bacher U, Haferlach T, Dicker F, Alpermann T, Kern W, Schnittger S
Leukemia 2011 May;25(5):874-7
PMID 21283084
 
Myelodysplastic syndrome/acute myeloid leukemia with t(3;21)(q26
Li S, Yin CC, Medeiros LJ, Bueso-Ramos C, Lu G, Lin P
2;q22) is commonly a therapy-related disease associated with poor outcome Am J Clin Pathol
PMID 22706870
 
Complex or monosomal karyotype and not blast percentage is associated with poor survival in acute myeloid leukemia and myelodysplastic syndrome patients with inv(3)(q21q26
Rogers HJ, Vardiman JW, Anastasi J, Raca G, Savage NM, Cherry AM, Arber D, Moore E, Morrissette JJ, Bagg A, Liu YC, Mathew S, Orazi A, Lin P, Wang SA, Bueso-Ramos CE, Foucar K, Hasserjian RP, Tiu RV, Karafa M, Hsi ED
2)/t(3;3)(q21;q26 2): a Bone Marrow Pathology Group study
PMID 24463215
 
Incidence and prognostic significance of karyotypic subgroups in older patients with acute myeloid leukemia: the Swedish population-based experience
Lazarevic V, Hörstedt AS, Johansson B, Antunovic P, Billström R, Derolf A, Hulegårdh E, Lehmann S, Möllgård L, Nilsson C, Peterson S, Stockelberg D, Uggla B, Wennström L, Wahlin A, Höglund M, Juliusson G
Blood Cancer J 2014 Feb 28;4:e188
PMID 24583534
 
A single oncogenic enhancer rearrangement causes concomitant EVI1 and GATA2 deregulation in leukemia
Gröschel S, Sanders MA, Hoogenboezem R, de Wit E, Bouwman BAM, Erpelinck C, van der Velden VHJ, Havermans M, Avellino R, van Lom K, Rombouts EJ, van Duin M, Döhner K, Beverloo HB, Bradner JE, Döhner H, Löwenberg B, Valk PJM, Bindels EMJ, de Laat W, Delwel R
Cell 2014 Apr 10;157(2):369-381
PMID 24703711
 
The landscape and therapeutic relevance of cancer-associated transcript fusions
Yoshihara K, Wang Q, Torres-Garcia W, Zheng S, Vegesna R, Kim H, Verhaak RG
Oncogene 2015 Sep 10;34(37):4845-54
PMID 25500544
 
Acute leukemia with abnormal thrombopoiesis and inversions of chromosome 3
Jenkins RB, Tefferi A, Solberg LA Jr, Dewald GW
Cancer Genet Cytogenet 1989 Jun;39(2):167-79
PMID 2752370
 
Clinical correlations of the 3q21;q26 cytogenetic anomaly
Pintado T, Ferro MT, San Román C, Mayayo M, Laraña JG
A leukemic or myelodysplastic syndrome with preserved or increased platelet production and lack of response to cytotoxic drug therapy Cancer
PMID 3965107
 
Rearrangements of chromosome 3 involving bands 3q21 and 3q26 are associated with normal or elevated platelet counts in acute nonlymphocytic leukemia
Bitter MA, Neilly ME, Le Beau MM, Pearson MG, Rowley JD
Blood 1985 Dec;66(6):1362-70
PMID 4063525
 
The predictive value of initial cytogenetic studies in 148 adults with acute nonlymphocytic leukemia: a 12-year study (1970-1982)
Larson RA, Le Beau MM, Vardiman JW, Testa JR, Golomb HM, Rowley JD
Cancer Genet Cytogenet 1983 Nov;10(3):219-36
PMID 6627222
 
Chromosome 3 abnormalities in acute nonlymphocytic leukemia (ANLL) with abnormal thrombopoiesis: report of three patients with a "new" inversion anomaly and a further case of homologous translocation
Bernstein R, Pinto MR, Behr A, Mendelow B
Blood 1982 Sep;60(3):613-7
PMID 7104489
 
Correlation of clinical findings with quinacrine-banded chromosomes in 90 adults with acute nonlymphocytic leukemia: an eight-year study (1970-1977)
Golomb HM, Vardiman JW, Rowley JD, Testa JR, Mintz U
N Engl J Med 1978 Sep 21;299(12):613-9
PMID 79982
 
Correlation of cytogenetic findings with clinical features in 18 patients with inv(3)(q21q26) or t(3;3)(q21;q26)
Fonatsch C, Gudat H, Lengfelder E, Wandt H, Silling-Engelhardt G, Ludwig WD, Thiel E, Freund M, Bodenstein H, Schwieder G, et al
Leukemia 1994 Aug;8(8):1318-26
PMID 8057667
 
Clinical, haematological and cytogenetic features in 24 patients with structural rearrangements of the Q arm of chromosome 3
Grigg AP, Gascoyne RD, Phillips GL, Horsman DE
Br J Haematol 1993 Jan;83(1):158-65
PMID 8435325
 
Abnormalities of 3q21 and 3q26 in myeloid malignancy: a United Kingdom Cancer Cytogenetic Group study
Secker-Walker LM, Mehta A, Bain B
Br J Haematol 1995 Oct;91(2):490-501
PMID 8547101
 
Activation of a novel gene in 3q21 and identification of intergenic fusion transcripts with ecotropic viral insertion site I in leukemia
Pekarsky Y, Rynditch A, Wieser R, Fonatsch C, Gardiner K
Cancer Res 1997 Sep 15;57(18):3914-9
PMID 9307271
 
The inv(3)(q21q26)/t(3;3)(q21;q26) is frequently accompanied by alterations of the RUNX1, KRAS and NRAS and NF1 genes and mediates adverse prognosis both in MDS and in AML: a study in 39 cases of MDS or AML
Haferlach C, Bacher U, Haferlach T, Dicker F, Alpermann T, Kern W, Schnittger S
Leukemia 2011 May;25(5):874-7
PMID 21283084
 
Myelodysplastic syndrome with inv(3)(q21q26
Cui W, Sun J, Cotta CV, Medeiros LJ, Lin P
2) or t(3;3)(q21;q26 2) has a high risk for progression to acute myeloid leukemia
PMID 21757602
 
Myelodysplastic syndrome/acute myeloid leukemia with t(3;21)(q26
Li S, Yin CC, Medeiros LJ, Bueso-Ramos C, Lu G, Lin P
2;q22) is commonly a therapy-related disease associated with poor outcome Am J Clin Pathol
PMID 22706870
 
Complex or monosomal karyotype and not blast percentage is associated with poor survival in acute myeloid leukemia and myelodysplastic syndrome patients with inv(3)(q21q26
Rogers HJ, Vardiman JW, Anastasi J, Raca G, Savage NM, Cherry AM, Arber D, Moore E, Morrissette JJ, Bagg A, Liu YC, Mathew S, Orazi A, Lin P, Wang SA, Bueso-Ramos CE, Foucar K, Hasserjian RP, Tiu RV, Karafa M, Hsi ED
2)/t(3;3)(q21;q26 2): a Bone Marrow Pathology Group study
PMID 24463215
 
A single oncogenic enhancer rearrangement causes concomitant EVI1 and GATA2 deregulation in leukemia
Gröschel S, Sanders MA, Hoogenboezem R, de Wit E, Bouwman BAM, Erpelinck C, van der Velden VHJ, Havermans M, Avellino R, van Lom K, Rombouts EJ, van Duin M, Döhner K, Beverloo HB, Bradner JE, Döhner H, Löwenberg B, Valk PJM, Bindels EMJ, de Laat W, Delwel R
Cell 2014 Apr 10;157(2):369-381
PMID 24703711
 
Identification of a breakpoint cluster region 3' of the ribophorin I gene at 3q21 associated with the transcriptional activation of the EVI1 gene in acute myelogenous leukemias with inv(3)(q21q26)
Suzukawa K, Parganas E, Gajjar A, Abe T, Takahashi S, Tani K, Asano S, Asou H, Kamada N, Yokota J, et al
Blood 1994 Oct 15;84(8):2681-8
PMID 7919381
 
Clinical, haematological and cytogenetic features in 24 patients with structural rearrangements of the Q arm of chromosome 3
Grigg AP, Gascoyne RD, Phillips GL, Horsman DE
Br J Haematol 1993 Jan;83(1):158-65
PMID 8435325
 
Abnormalities of 3q21 and 3q26 in myeloid malignancy: a United Kingdom Cancer Cytogenetic Group study
Secker-Walker LM, Mehta A, Bain B
Br J Haematol 1995 Oct;91(2):490-501
PMID 8547101
 
The inv(3)(q21q26)/t(3;3)(q21;q26) is frequently accompanied by alterations of the RUNX1, KRAS and NRAS and NF1 genes and mediates adverse prognosis both in MDS and in AML: a study in 39 cases of MDS or AML
Haferlach C, Bacher U, Haferlach T, Dicker F, Alpermann T, Kern W, Schnittger S
Leukemia 2011 May;25(5):874-7
PMID 21283084
 
Myelodysplastic syndrome with inv(3)(q21q26
Cui W, Sun J, Cotta CV, Medeiros LJ, Lin P
2) or t(3;3)(q21;q26 2) has a high risk for progression to acute myeloid leukemia
PMID 21757602
 
Myelodysplastic syndrome/acute myeloid leukemia with t(3;21)(q26
Li S, Yin CC, Medeiros LJ, Bueso-Ramos C, Lu G, Lin P
2;q22) is commonly a therapy-related disease associated with poor outcome Am J Clin Pathol
PMID 22706870
 
Complex or monosomal karyotype and not blast percentage is associated with poor survival in acute myeloid leukemia and myelodysplastic syndrome patients with inv(3)(q21q26
Rogers HJ, Vardiman JW, Anastasi J, Raca G, Savage NM, Cherry AM, Arber D, Moore E, Morrissette JJ, Bagg A, Liu YC, Mathew S, Orazi A, Lin P, Wang SA, Bueso-Ramos CE, Foucar K, Hasserjian RP, Tiu RV, Karafa M, Hsi ED
2)/t(3;3)(q21;q26 2): a Bone Marrow Pathology Group study
PMID 24463215
 
A single oncogenic enhancer rearrangement causes concomitant EVI1 and GATA2 deregulation in leukemia
Gröschel S, Sanders MA, Hoogenboezem R, de Wit E, Bouwman BAM, Erpelinck C, van der Velden VHJ, Havermans M, Avellino R, van Lom K, Rombouts EJ, van Duin M, Döhner K, Beverloo HB, Bradner JE, Döhner H, Löwenberg B, Valk PJM, Bindels EMJ, de Laat W, Delwel R
Cell 2014 Apr 10;157(2):369-381
PMID 24703711
 
Identification of a breakpoint cluster region 3' of the ribophorin I gene at 3q21 associated with the transcriptional activation of the EVI1 gene in acute myelogenous leukemias with inv(3)(q21q26)
Suzukawa K, Parganas E, Gajjar A, Abe T, Takahashi S, Tani K, Asano S, Asou H, Kamada N, Yokota J, et al
Blood 1994 Oct 15;84(8):2681-8
PMID 7919381
 
Clinical, haematological and cytogenetic features in 24 patients with structural rearrangements of the Q arm of chromosome 3
Grigg AP, Gascoyne RD, Phillips GL, Horsman DE
Br J Haematol 1993 Jan;83(1):158-65
PMID 8435325
 
Abnormalities of 3q21 and 3q26 in myeloid malignancy: a United Kingdom Cancer Cytogenetic Group study
Secker-Walker LM, Mehta A, Bain B
Br J Haematol 1995 Oct;91(2):490-501
PMID 8547101
 
The inv(3)(q21q26)/t(3;3)(q21;q26) is frequently accompanied by alterations of the RUNX1, KRAS and NRAS and NF1 genes and mediates adverse prognosis both in MDS and in AML: a study in 39 cases of MDS or AML
Haferlach C, Bacher U, Haferlach T, Dicker F, Alpermann T, Kern W, Schnittger S
Leukemia 2011 May;25(5):874-7
PMID 21283084
 
Myelodysplastic syndrome with inv(3)(q21q26
Cui W, Sun J, Cotta CV, Medeiros LJ, Lin P
2) or t(3;3)(q21;q26 2) has a high risk for progression to acute myeloid leukemia
PMID 21757602
 
Myelodysplastic syndrome/acute myeloid leukemia with t(3;21)(q26
Li S, Yin CC, Medeiros LJ, Bueso-Ramos C, Lu G, Lin P
2;q22) is commonly a therapy-related disease associated with poor outcome Am J Clin Pathol
PMID 22706870
 
Complex or monosomal karyotype and not blast percentage is associated with poor survival in acute myeloid leukemia and myelodysplastic syndrome patients with inv(3)(q21q26
Rogers HJ, Vardiman JW, Anastasi J, Raca G, Savage NM, Cherry AM, Arber D, Moore E, Morrissette JJ, Bagg A, Liu YC, Mathew S, Orazi A, Lin P, Wang SA, Bueso-Ramos CE, Foucar K, Hasserjian RP, Tiu RV, Karafa M, Hsi ED
2)/t(3;3)(q21;q26 2): a Bone Marrow Pathology Group study
PMID 24463215
 
A single oncogenic enhancer rearrangement causes concomitant EVI1 and GATA2 deregulation in leukemia
Gröschel S, Sanders MA, Hoogenboezem R, de Wit E, Bouwman BAM, Erpelinck C, van der Velden VHJ, Havermans M, Avellino R, van Lom K, Rombouts EJ, van Duin M, Döhner K, Beverloo HB, Bradner JE, Döhner H, Löwenberg B, Valk PJM, Bindels EMJ, de Laat W, Delwel R
Cell 2014 Apr 10;157(2):369-381
PMID 24703711
 
Clinical, haematological and cytogenetic features in 24 patients with structural rearrangements of the Q arm of chromosome 3
Grigg AP, Gascoyne RD, Phillips GL, Horsman DE
Br J Haematol 1993 Jan;83(1):158-65
PMID 8435325
 
Abnormalities of 3q21 and 3q26 in myeloid malignancy: a United Kingdom Cancer Cytogenetic Group study
Secker-Walker LM, Mehta A, Bain B
Br J Haematol 1995 Oct;91(2):490-501
PMID 8547101
 
A single oncogenic enhancer rearrangement causes concomitant EVI1 and GATA2 deregulation in leukemia
Gröschel S, Sanders MA, Hoogenboezem R, de Wit E, Bouwman BAM, Erpelinck C, van der Velden VHJ, Havermans M, Avellino R, van Lom K, Rombouts EJ, van Duin M, Döhner K, Beverloo HB, Bradner JE, Döhner H, Löwenberg B, Valk PJM, Bindels EMJ, de Laat W, Delwel R
Cell 2014 Apr 10;157(2):369-381
PMID 24703711
 
A single oncogenic enhancer rearrangement causes concomitant EVI1 and GATA2 deregulation in leukemia
Gröschel S, Sanders MA, Hoogenboezem R, de Wit E, Bouwman BAM, Erpelinck C, van der Velden VHJ, Havermans M, Avellino R, van Lom K, Rombouts EJ, van Duin M, Döhner K, Beverloo HB, Bradner JE, Döhner H, Löwenberg B, Valk PJM, Bindels EMJ, de Laat W, Delwel R
Cell 2014 Apr 10;157(2):369-381
PMID 24703711
 
Clinical and prognostic significance of 3q26
Wang W, Cortes JE, Lin P, Beaty MW, Ai D, Amin HM, McDonnell TJ, Ok CY, Kantarjian HM, Medeiros LJ, Hu S
2 and other chromosome 3 abnormalities in CML in the era of tyrosine kinase inhibitors Blood
PMID 26243778
 
Cytogenetic correlation with disease status and treatment outcome in advanced stage leukemia post bone marrow transplantation: a Southwest Oncology Group study (SWOG-8612)
Slovak ML, Kopecky KJ, Wolman SR, Henslee-Downey JP, Appelbaum FR, Forman SJ, Blume KG
Leuk Res 1995 Jun;19(6):381-8
PMID 7596150
 
Abnormalities of 3q21 and 3q26 in myeloid malignancy: a United Kingdom Cancer Cytogenetic Group study
Secker-Walker LM, Mehta A, Bain B
Br J Haematol 1995 Oct;91(2):490-501
PMID 8547101
 
Structurally altered Evi-1 protein generated in the 3q21q26 syndrome
Ogawa S, Kurokawa M, Tanaka T, Mitani K, Inazawa J, Hangaishi A, Tanaka K, Matsuo Y, Minowada J, Tsubota T, Yazaki Y, Hirai H
Oncogene 1996 Jul 4;13(1):183-91
PMID 8700545
 
Identification of translocational breakpoints within the intron region before the last coding exon (exon 12) of the EVI1 gene in two cases of CML-BC with inv(3)(q21q26)
Suzukawa K, Taki T, Abe T, Asoh H, Kamada N, Yokota J, Morishita K
Genomics 1997 Jun 1;42(2):356-60
PMID 9192861
 


Translocations implicated (Data extracted from papers in the Atlas)

 inv(3)(q21q26):t(3;3)(q21;q26):t(3;3)(q26;q21) GATA2/MECOM

External links

GATA2 (3q21.3) MECOM (3q26.2)

Mitelman databaseinv(3)(q21q26):t(3;3)(q21;q26):t(3;3)(q26;q21) [Case List]    inv(3)(q21q26):t(3;3)(q21;q26):t(3;3)(q26;q21) [Transloc-MCList] GATA2/MECOM [Fusion-MCList]
COSMICHisto = - Site = haematopoietic_and_lymphoid_tissue (COSMIC)
arrayMap (UZH-SIB Zurich)[select an item]
 
 
REVIEW articlesautomatic search in PubMed
Last year articlesautomatic search in PubMed
All articlesautomatic search in PubMed


© Atlas of Genetics and Cytogenetics in Oncology and Haematology
indexed on : Wed Jan 10 17:21:03 CET 2018


Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

For comments and suggestions or contributions, please contact us

jlhuret@AtlasGeneticsOncology.org.